Characterization of CD133(+)/CD44(+) human prostate cancer stem cells with ATR-FTIR spectroscopy

Basit Öğe Kaydı
dc.contributor.authorGuler, Gunnur
dc.contributor.authorGuven, Ummu
dc.contributor.authorOktem, Gulperi
dc.date.accessioned2019-10-27T09:45:28Z
dc.date.available2019-10-27T09:45:28Z
dc.date.issued2019
dc.departmentEge Üniversitesien_US
dc.description.abstractCurrent cancer treatments destroy the tumor mass but cannot prevent the recurrence of cancer. The heterogeneous structure of the tumor mass includes cancer stem cells that are responsible for tumor relapse, treatment resistance, invasion and metastasis. The biology of these cells is still not fully understood; therefore, effective treatments cannot be developed sufficiently. Herein, attenuated total reflection- Fourier transform infrared (ATR-FTIR) spectroscopy, combined with unsupervised multivariate analysis, was applied to prostate cancer stem cells (CSCs), non-stem cancer cells (non-CSCs) and normal prostate epithelial cells to elucidate the molecular mechanisms and features of CSCs, which are crucial to improving the target specific therapies. This work revealed the spectral differences in the cellular mechanisms and biochemical structures among three different cell types. Particularly, prostate CSCs exhibit differences in the lipid composition and dynamics when compared to other cell types. CSCs also harbor pronounced differences in their major cellular macromolecules, including differences in the protein amount and content (mainly a-helices), the abundance of nucleic acids (DNA/RNA), altered nucleic acid conformation and carbohydrate composition. Interestingly, macromolecules containing the CvO groups and negatively charged molecules having the COO-groups are abundant in prostate CSCs in comparison to prostate non-CSCs and normal prostate cells. Overall, this study demonstrates the potential use of ATR-FTIR spectroscopy as a powerful tool to obtain new insights into the understanding of the CSC features, which may provide new strategies for cancer treatment by selectively targeting the CSCs.en_US
dc.identifier.doi10.1039/c9an00093c
dc.identifier.endpage2149en_US
dc.identifier.issn0003-2654
dc.identifier.issn1364-5528
dc.identifier.issue6en_US
dc.identifier.startpage2138en_US
dc.identifier.urihttps://doi.org/10.1039/c9an00093c
dc.identifier.urihttps://hdl.handle.net/11454/29148
dc.identifier.volume144en_US
dc.identifier.wosWOS:000460765600028en_US
dc.identifier.wosqualityQ1en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.language.isoenen_US
dc.publisherRoyal Soc Chemistryen_US
dc.relation.ispartofAnalysten_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.titleCharacterization of CD133(+)/CD44(+) human prostate cancer stem cells with ATR-FTIR spectroscopyen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu